| Identification | Back Directory | [Name]
PropanaMide,2-hydroxy-2-Methyl-N-[4-nitro-3-(trifluoroMethyl)phenyl]-3-[(2,2,2-trifluoroacetyl)aMino | [CAS]
260980-89-0 | [Synonyms]
BP766
Fluridil
Topilutamide
Fluridil (Topilutamide)
2-hydroxy-2-methyl-N-(4-nitro-3-(trifluoromethyl)phenyl)-3-(2,2,2-trifluoroacetamido)propanamide
PropanaMide,2-hydroxy-2-Methyl-N-[4-nitro-3-(trifluoroMethyl)phenyl]-3-[(2,2,2-trifluoroacetyl)aMino
(2R)-2-hydroxy-2-methyl-N-[4-nitro-3-(trifluoromethyl)phenyl]-3-[(2,2,2-trifluoroacetyl)amino]propanamide | [Molecular Formula]
C13H11F6N3O5 | [MDL Number]
MFCD30532579 | [MOL File]
260980-89-0.mol | [Molecular Weight]
403.23 |
| Chemical Properties | Back Directory | [Melting point ]
144-145 °C | [Boiling point ]
284-289 °C | [density ]
1.588±0.06 g/cm3(Predicted) | [storage temp. ]
Store at -20°C | [solubility ]
DMSO : 150 mg/mL (372.00 mM) | [form ]
Solid | [pka]
10.66±0.46(Predicted) | [color ]
White to off-white | [Cosmetics Ingredients Functions]
HAIR CONDITIONING | [InChI]
InChI=1S/C13H11F6N3O5/c1-11(25,5-20-10(24)13(17,18)19)9(23)21-6-2-3-8(22(26)27)7(4-6)12(14,15)16/h2-4,25H,5H2,1H3,(H,20,24)(H,21,23) | [InChIKey]
YCNCRLKXSLARFT-UHFFFAOYSA-N | [SMILES]
C(NC1=CC=C([N+]([O-])=O)C(C(F)(F)F)=C1)(=O)C(O)(C)CNC(C(F)(F)F)=O |
| Hazard Information | Back Directory | [Uses]
Topilutamide is a topical nonsteroidal antiandrogen (NSAA). | [in vivo]
Prostate cancer is the most common cancer and one of the leading causes of cancer deaths in men. One of the commonly used approaches to treat metastatic prostate cancer is via first-generation nonsteroidal anti-androgens (NSAAs), namely Flutamide, Nilutamide, Bicalutamide and Topilutamide[1]. | [References]
[1] Suresh PS, et al. Review of HPLC and LC-MS/MS assays for the determination of various nonsteroidal anti-androgens used in the treatment of prostate cancer. Biomed Chromatogr. 2017 Jun 21. DOI:10.1002/bmc.4034
[2] Sovak M, Seligson AL, Kucerova R, Bienova M, Hajduch M, Bucek M. Fluridil, a rationally designed topical agent for androgenetic alopecia: first clinical experience [published correction appears in Dermatol Surg 2002 Oct;28(8):following 970]. Dermatol Surg. 2002;28(8):678-685. DOI:10.1046/j.1524-4725.2002.02017.x |
|
|